Table 1. Experimental Parameters Patient... | American Society of Hematology

Table 1.

Experimental Parameters

Patient and Sample Characteristics								Growth in SCID-hu Hosts
Patient	Stage^*	Prior Rx	M Isotype	Sample	(%) PC^†	PC L.I.^‡	% CD19	Cont.^1-153	Cells (×10⁶)^1-155	PC^1-154	Cells (×10⁶)^1-155	PC- Depleted#	Cells (×10⁶)^1-155
1	III A	Y	IgG κ	BM	78	2.8	ND	Y	3	Y	3.2	ND	—
2	III A	N	IgA κ	BM	40	1.2	ND	Y	3	Y	2.7	N	0.8
3	III A	Y	IgG κ	BM	26	2.4	ND	Y	3	N	0.7	ND	—
4	III A	Y	IgA κ	BM	35	ND	ND	Y	2	Y	1	ND	—
5	III A	Y	κ light chain	BM	75	ND	ND	Y	5	Y	2	N	0.5
6	III A	N	Nonsecretor	BM	38	3.2	ND	Y	5	Y	3	N	3
7	III A	N	IgG λ	BM	50	0.2	ND	Y	4	Y	2.6	N	2.7
8	III-B	N	IgG κ	BM	64	0.6	ND	Y	4	Y	2.8	N	3.5
9	III B	Y	λ light chain	BM	48	0	ND	Y	5	Y	2	N	2
				PB	7.5	ND	4	Y	10	ND	—	N	14
10	III A	N	IgG κ	BM	11	0.4	ND	Y	5	ND	—	ND	—
				PB	0.1	ND	10	Y	10	ND	—	N	5
11	III A	Y	IgG κ	BM	11	ND	ND	Y	10	ND	—	ND	—
				PB	0	—	9	N	10	—	—	—	—
12	I A	N	IgG κ	BM	30	ND	ND	Y	5	ND	—	ND	—
				PB	0.4	ND	0	Y	10	ND	—	ND	—
13	III	N	IgG κ	BM	48	0.6	ND	ND	—	ND	—	ND	—
				PB	14	ND	18	Y	2	ND	—	N	1.5

Patient and Sample Characteristics								Growth in SCID-hu Hosts
Patient	Stage^*	Prior Rx	M Isotype	Sample	(%) PC^†	PC L.I.^‡	% CD19	Cont.^1-153	Cells (×10⁶)^1-155	PC^1-154	Cells (×10⁶)^1-155	PC- Depleted#	Cells (×10⁶)^1-155
1	III A	Y	IgG κ	BM	78	2.8	ND	Y	3	Y	3.2	ND	—
2	III A	N	IgA κ	BM	40	1.2	ND	Y	3	Y	2.7	N	0.8
3	III A	Y	IgG κ	BM	26	2.4	ND	Y	3	N	0.7	ND	—
4	III A	Y	IgA κ	BM	35	ND	ND	Y	2	Y	1	ND	—
5	III A	Y	κ light chain	BM	75	ND	ND	Y	5	Y	2	N	0.5
6	III A	N	Nonsecretor	BM	38	3.2	ND	Y	5	Y	3	N	3
7	III A	N	IgG λ	BM	50	0.2	ND	Y	4	Y	2.6	N	2.7
8	III-B	N	IgG κ	BM	64	0.6	ND	Y	4	Y	2.8	N	3.5
9	III B	Y	λ light chain	BM	48	0	ND	Y	5	Y	2	N	2
				PB	7.5	ND	4	Y	10	ND	—	N	14
10	III A	N	IgG κ	BM	11	0.4	ND	Y	5	ND	—	ND	—
				PB	0.1	ND	10	Y	10	ND	—	N	5
11	III A	Y	IgG κ	BM	11	ND	ND	Y	10	ND	—	ND	—
				PB	0	—	9	N	10	—	—	—	—
12	I A	N	IgG κ	BM	30	ND	ND	Y	5	ND	—	ND	—
				PB	0.4	ND	0	Y	10	ND	—	ND	—
13	III	N	IgG κ	BM	48	0.6	ND	ND	—	ND	—	ND	—
				PB	14	ND	18	Y	2	ND	—	N	1.5

Abbreviations: ND, experiment not done; Y, SCID-hu hosts developed myeloma; N, hosts did not develop myeloma.

Stage according to the Durie Salmon staging.

Percent plasma cells in sample, determined by CD38/CD45 flow cytometry.

BudR labeling index of light chain clg restricted plasma cells.

Unseparated BM or PB cells inoculated into SCID-hu hosts as controls for myeloma development.

Total number of cells inoculated.

SCID-hu hosts injected with purified myeloma plasma cells.

#SCID-hu hosts injected with PC-depleted cells.